China In–Vitro Diagnostics(IVD) Market, By Segment (Clinical Chemistry, Immunoassay, Molecular Testing, Microbiology, Hematology, SMBG, POCT, Coagulation), Companies
In China, in vitro diagnostic industry has been emerged since the 1980s, and now the key players are manufacturing from single and straight forward products to complete industrial chains. The 21st century brought a rapid development in China IVD industry, where all the tools such as reagents and instruments are produced in-house. Nowadays the global companies have put their steps in China and engaged in business activities of in vitro diagnostic industry. The increasing number of test volumes related to clinical chemistry, immunoassay, haematology, coagulation and microbiology are in high demand. They are acting as a catalysing role for the growth of the China IVD industry. According to Renub Research analysis, China In Vitro Diagnostics Market will be USD 22.3 Billion by 2026.
The major growth drivers for China IVD industry are increasing demand from the middle class for high-quality healthcare products, and rising incidences of lifestyle diseases. In China, there has been massive expenditure in every healthcare segment in the areas of pharmaceuticals, medical devices, and traditional Chinese medicines. The significant barriers for China IVD industry are the local manufacturers lagging by the adoption of advance technology.
In October 2020, Roche diagnostics launched the product "Roche’s Tecentriq" with Avastin which was approved by CFDA for the treatment of liver cancer. The outbreak of Covid-19 has impacted the IVD products by playing a vital role in the diagnosis of the coronavirus symptoms.
Renub Research report titled “China In–Vitro Diagnostics (IVD) Market, By Segment [Clinical Chemistry, Immunoassay, Molecular Testing, Microbiology, Hematology, Self Monitoring of Blood Glucose (SMBG), Point of Care Testing (POCT), Coagulation], Companies (Roche Diagnostics, Sysmex Corporation, Mindray Medical International Limited, Shanghai Kehua Bio-Engineering Co. Ltd., Abbott Laboratories & Others)” studies the China IVD Industry.
By Segment – The Report Studies the Market of the following 8 Categories
1. Clinical Chemistry
2. Immunoassay
3. Molecular Testing
4. Microbiology
5. Hematology
6. Self Monitoring of Blood Glucose (SMBG)
7. Point of Care Testing (POCT)
8. Coagulation
Key Players covered in the report which has been studied from 3 viewpoints
1. Roche Diagnostics
2. Sysmex Corporation
3. Mindray Medical International Limited
4. Shanghai Kehua Bio-Engineering Co. Ltd.
5. Abbott Laboratories
The major growth drivers for China IVD industry are increasing demand from the middle class for high-quality healthcare products, and rising incidences of lifestyle diseases. In China, there has been massive expenditure in every healthcare segment in the areas of pharmaceuticals, medical devices, and traditional Chinese medicines. The significant barriers for China IVD industry are the local manufacturers lagging by the adoption of advance technology.
In October 2020, Roche diagnostics launched the product "Roche’s Tecentriq" with Avastin which was approved by CFDA for the treatment of liver cancer. The outbreak of Covid-19 has impacted the IVD products by playing a vital role in the diagnosis of the coronavirus symptoms.
Renub Research report titled “China In–Vitro Diagnostics (IVD) Market, By Segment [Clinical Chemistry, Immunoassay, Molecular Testing, Microbiology, Hematology, Self Monitoring of Blood Glucose (SMBG), Point of Care Testing (POCT), Coagulation], Companies (Roche Diagnostics, Sysmex Corporation, Mindray Medical International Limited, Shanghai Kehua Bio-Engineering Co. Ltd., Abbott Laboratories & Others)” studies the China IVD Industry.
By Segment – The Report Studies the Market of the following 8 Categories
1. Clinical Chemistry
2. Immunoassay
3. Molecular Testing
4. Microbiology
5. Hematology
6. Self Monitoring of Blood Glucose (SMBG)
7. Point of Care Testing (POCT)
8. Coagulation
Key Players covered in the report which has been studied from 3 viewpoints
- Overview
- Initiatives & Recent Developments
- Revenue
1. Roche Diagnostics
2. Sysmex Corporation
3. Mindray Medical International Limited
4. Shanghai Kehua Bio-Engineering Co. Ltd.
5. Abbott Laboratories
China In Vitro Diagnostics Market will be USD 22.3 Billion by 2026. Forecast by Segment (Clinical Chemistry, Immunoassay, Molecular Testing, Microbiology, Hematology, SMBG, Point of Care Testing, Coagulation), Company Analysis.
